Abstract:Background and purpose: Targeting Wnt/β-catenin signaling emerges as one of the promising strategies for colorectal cancer (CRC) treatment, as this signaling is highly activated in CRC progression. Despite reports on the cytotoxic effects of hirsutine (HT), an indole alkaloid found in herbal medicines from the genus Uncaria, its therapeutic potential for CRC and the involved mechanisms are poorly understood. This study investigates the anticancer efficacy and the probable mechanisms of HT against CRC. Methods: To evaluate in vitro anticancer activity of HT, cell growth examined by MTT and colony formation assay, and apoptosis examined by flow cytometry were analyzed. To explore the mechanisms, RNA-sequencing, western blotting, dual-luciferase reporter assays, immunofluorescence, and co-immunoprecipitation were performed. Mouse model of azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colon cancer was utilized to assess HT's in vivo anticancer efficacy. Results: HT significantly inhibited CRC cell proliferation with IC50 values of 22.25 ± 3.27 μM for SW620 cells and 22.24 ± 2.36 μM for HCT116 cells, and induced apoptosis. HT decreased protein levels of Wnt3a and β-catenin dose- and time-dependently, and inhibited TOP/FOP FLASH reporter activity, nuclear travel of β-catenin, and downstream targets like c-Myc, Cyclin D1, VEGF. HT reduced β-catenin protein half-life, and the reversal of this effect by MG132 indicated that HT facilitated proteasome-dependent degradation of β-catenin in these two cell lines. HT also increased β-catenin ubiquitination without affecting Axin and β-TrCP levels. HT treatment for 24 h induced YAP cytoplasmic retention, enhanced YAP interacting with β-catenin and β-TrCP, triggering destruction complex formation and β-catenin ubiquitination and degradation, while YAP siRNA impaired these effects. Additionally, β-catenin overexpression and LiCl treatment counteracted HT-induced inhibition on cell growth and Wnt/β-catenin cascade. In model of AOM/DSS-induced mouse colon cancer, compared with AOM/DSS treatment group, HT recovered colon length, reduced tumor numbers and radius, and downregulated β-catenin and Ki-67, while upregulated cleaved PARP in the colorectal tissue with tumors. Conclusion: HT exhibits anticancer activity against CRC probably by inhibiting Wnt/β-catenin signaling, with YAP playing an indispensible role during the process, highlighting HT as a potential novel candidate drug for CRC therapy.

A Novel Oxaliplatin Derivative, Ht-2, Triggers Mitochondrion-Dependent Apoptosis in Human Colon Cancer Cells.

Homoharringtonine Inhibits the Akt Pathway and Induces in Vitro and in Vivo Cytotoxicity in Human Multiple Myeloma Cells

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.

HMGA2 Promotes Resistance Against Paclitaxel by Targeting the P53 Signaling Pathway in Colorectal Cancer Cells

Oxaliplatin Induces Apoptosis in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway

Effect of tanshinone II a combined with oxaliplatin on human hepatocellular carcinoma cell line SMMC-7721

Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer

Novel Mitochondrion-Targeting Copper(ii) Complex Induces HK2 Malfunction and Inhibits Glycolysis Via Drp1-mediating Mitophagy in HCC

A novel pyrrolidine-2,5-dione derivative induced G2/M phase arrest and apoptosis of hepatocellular carcinoma HepG2 cells through inhibiting tubulin polymerization

Oxaliplatin promotes siMAD2L2‐induced apoptosis in colon cancer cells

Chrysotoxene Induces Apoptosis of Human Hepatoblastoma HepG2 Cells Inï¿½vitro and Inï¿½vivo Via Activation of the Mitochondria-Mediated Apoptotic Signaling Pathway

XQ2, a Novel TPZ Derivative, Induced G2/M Phase Arrest and Apoptosis under Hypoxia in Non-Small Cell Lung Cancer Cells

Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy

Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism

Pentoxifylline Induces Apoptosis of HepG2 Cells by Reducing Reactive Oxygen Species Production and Activating the MAPK Signaling.

Yes-associated protein indispensably mediates hirsutine-induced inhibition on cell growth and Wnt/β-catenin signaling in colorectal cancer

Prediction and verification of targets for α-hederin/oxaliplatin dual-loaded rHDL modified liposomes: Reversing effector T-cells dysfunction and improving anti-COAD efficiency in vitro and in vivo

The Effects of Combination Chemotherapy of Hydroxycampothecin with Oxaliplatin on Human Colorectal Cancer Cell Line